• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparing Primary Prevention Recommendations: A Focused Look at United States and European Guidelines on Dyslipidemia.

作者信息

Stone Neil J, Blumenthal Roger S, Lloyd-Jones Donald, Grundy Scott M

机构信息

Departments of Medicine (Cardiology) and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois (N.J.S., D.L.-L.).

Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins Hospital, Baltimore, MD (R.S.B.).

出版信息

Circulation. 2020 Apr 7;141(14):1117-1120. doi: 10.1161/CIRCULATIONAHA.119.044562. Epub 2020 Apr 6.

DOI:10.1161/CIRCULATIONAHA.119.044562
PMID:32250697
Abstract
摘要

相似文献

1
Comparing Primary Prevention Recommendations: A Focused Look at United States and European Guidelines on Dyslipidemia.比较一级预防建议：聚焦美国和欧洲血脂异常指南
Circulation. 2020 Apr 7;141(14):1117-1120. doi: 10.1161/CIRCULATIONAHA.119.044562. Epub 2020 Apr 6.
2
Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia.动脉粥样硬化性心血管疾病的二级预防：比较美国和欧洲近期关于血脂异常的指南
Circulation. 2020 Apr 7;141(14):1121-1123. doi: 10.1161/CIRCULATIONAHA.119.044282. Epub 2020 Apr 6.
3
Summary of 2016 ESC guidelines on heart failure, atrial fibrillation, dyslipidaemia and cardiovascular prevention.2016年欧洲心脏病学会关于心力衰竭、心房颤动、血脂异常及心血管疾病预防的指南摘要。
Acta Cardiol. 2017 Dec;72(6):610-615. doi: 10.1080/00015385.2017.1319681. Epub 2017 Jul 7.
4
[Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].[西班牙心血管疾病预防跨学科委员会及西班牙心脏病学会关于血脂异常管理的立场声明。欧洲和美国指南的差异]
Semergen. 2015 Apr;41(3):149-57. doi: 10.1016/j.semerg.2014.05.020. Epub 2014 Nov 14.
5
Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.欧洲心血管疾病一级预防中致动脉粥样硬化性血脂异常的患病率及治疗情况：EURIKA横断面观察性研究
BMC Cardiovasc Disord. 2017 Jun 17;17(1):160. doi: 10.1186/s12872-017-0591-5.
6
[Recommendations for management of dyslipidemia in 2016 in Switzerland].[2016年瑞士血脂异常管理建议]
Rev Med Suisse. 2016 Mar 2;12(508):430-4.
7
Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.根据心血管风险水平评估，法国普通人群中低密度脂蛋白胆固醇目标的达标情况：MONA LISA 研究的结果。
Arch Cardiovasc Dis. 2013 Feb;106(2):93-102. doi: 10.1016/j.acvd.2012.11.003. Epub 2013 Jan 16.
8
[Guidelines for the management of dyslipidemia].[血脂异常管理指南]
Semergen. 2014 Sep;40 Suppl 4:19-25. doi: 10.1016/S1138-3593(14)74393-X.
9
[Are therapeutic LDL goals justified? Controversies between the European and American guidelines].[治疗性低密度脂蛋白目标是否合理？欧美指南之间的争议]
Medwave. 2016 Dec 30;16(Suppl4):e6825. doi: 10.5867/medwave.2016.6825.
10
[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].[接受降脂治疗的血脂异常患者动脉粥样硬化性心血管疾病一级和二级预防中胆固醇目标达成情况：中国血脂异常防治研究（DYSIS-China）亚组分析]
Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Aug 24;44(8):665-70. doi: 10.3760/cma.j.issn.0253-3758.2016.08.006.

引用本文的文献

1
Atherosclerotic Cardiovascular Disease Risk Estimates Using the New Predicting Risk of Cardiovascular Disease Events Equations: Implications for Statin Use.使用新的心血管疾病事件风险预测方程评估动脉粥样硬化性心血管疾病风险：对他汀类药物使用的影响
Curr Cardiol Rep. 2025 Jul 2;27(1):107. doi: 10.1007/s11886-025-02244-5.
2
Metabolic diseases in the East Asian populations.东亚人群中的代谢性疾病。
Nat Rev Gastroenterol Hepatol. 2025 Apr 8. doi: 10.1038/s41575-025-01058-8.
3
Utility of bioelectrical phase angle for cardiovascular risk assessment among individuals with and without diabetes mellitus.
生物电相角在糖尿病患者和非糖尿病患者心血管风险评估中的应用。
Diab Vasc Dis Res. 2024 Jan-Feb;21(1):14791641231223701. doi: 10.1177/14791641231223701.
4
A case control study on the relationship between occupational stress and genetic polymorphism and dyslipidemia in coal miners.一项关于职业应激与遗传多态性和矿工血脂异常关系的病例对照研究。
Sci Rep. 2023 Feb 9;13(1):2321. doi: 10.1038/s41598-023-29491-2.
5
Assessment of Atherosclerotic Cardiovascular Disease Risk in Primary Prevention.在一级预防中评估动脉粥样硬化性心血管疾病风险。
J Cardiopulm Rehabil Prev. 2022 Nov 1;42(6):397-403. doi: 10.1097/HCR.0000000000000746.
6
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.迫切需要更早、更强化且更精准地治疗动脉粥样硬化性心血管疾病风险：当前实践综述及提高疗效的建议。
Am J Prev Cardiol. 2022 Aug 6;12:100371. doi: 10.1016/j.ajpc.2022.100371. eCollection 2022 Dec.
7
Aspirin and Statin Therapy for Nonobstructive Coronary Artery Disease: Five-year Outcomes from the CONFIRM Registry.阿司匹林和他汀类药物治疗非阻塞性冠状动脉疾病：CONFIRM注册研究的五年结果
Radiol Cardiothorac Imaging. 2022 Apr 28;4(2):e210225. doi: 10.1148/ryct.210225. eCollection 2022 Apr.
8
Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank.胆红素作为代谢心血管健康的指标：英国生物库的横断面分析。
Cardiovasc Diabetol. 2022 Apr 18;21(1):54. doi: 10.1186/s12933-022-01484-x.
9
Contemporary Management of Dyslipidemia.当代血脂异常管理。
Drugs. 2022 Apr;82(5):559-576. doi: 10.1007/s40265-022-01691-6. Epub 2022 Mar 18.
10
Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio-Experience from the Swedish AMORIS cohort: A cohort study.载脂蛋白 B、载脂蛋白 A-1 和载脂蛋白 B/载脂蛋白 A-1 比值与主要心血管事件长期风险的关系：来自瑞典 AMORIS 队列的经验：一项队列研究。
PLoS Med. 2021 Dec 1;18(12):e1003853. doi: 10.1371/journal.pmed.1003853. eCollection 2021 Dec.